Neurocrine Biosciences, Inc. – Product Pipeline Review – H2 2011

Date: November 1, 2011
Pages: 65
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N584F16DEF1EN
Leaflet:

Download PDF Leaflet

Neurocrine Biosciences, Inc. – Product Pipeline Review – H2 2011
Neurocrine Biosciences, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Neurocrine Biosciences, Inc. - Product Pipeline Review - H2 2011” provides data on the Neurocrine Biosciences, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Neurocrine Biosciences, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Neurocrine Biosciences, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Neurocrine Biosciences, Inc. - Brief Neurocrine Biosciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Neurocrine Biosciences, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Neurocrine Biosciences, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Neurocrine Biosciences, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy
  • Evaluate Neurocrine Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Neurocrine Biosciences, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Neurocrine Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Neurocrine Biosciences, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Neurocrine Biosciences, Inc. and identify potential opportunities in those areas.
Neurocrine Biosciences, Inc. Snapshot
Neurocrine Biosciences, Inc. Overview
Key Information
Key Facts
Neurocrine Biosciences, Inc. – Research and Development Overview
Key Therapeutic Areas
Neurocrine Biosciences, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Neurocrine Biosciences, Inc. – Pipeline Products Glance
Neurocrine Biosciences, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Neurocrine Biosciences, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Neurocrine Biosciences, Inc. – Drug Profiles
GPR119 Agonists
  Product Description
  Mechanism of Action
  R&D Progress
NBI-98854
  Product Description
  Mechanism of Action
  R&D Progress
Urocortin 2
  Product Description
  Mechanism of Action
  R&D Progress
Neurocrine Biosciences, Inc. – Pipeline Analysis
Neurocrine Biosciences, Inc. – Pipeline Products by Therapeutic Class
Neurocrine Biosciences, Inc. - Pipeline Products By Target
Neurocrine Biosciences, Inc. – Pipeline Products by Route of Administration
Neurocrine Biosciences, Inc. – Pipeline Products by Molecule Type
Neurocrine Biosciences, Inc. – Recent Pipeline Updates
Neurocrine Biosciences, Inc. - Dormant Projects
Neurocrine Biosciences, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
NBI-5788
DHEA
Indiplon
Indiplon + Sertraline
NBI-42902
NBI-6024
R121919
Neurocrine Biosciences, Inc. – Company Statement
Neurocrine Biosciences, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 30, 1999: NBI-34060 Shows Positive Results For Sleep Induction
Jul 30, 2007: Neurocrine Biosciences In-Licenses Clinical Compound: Valnoctamide Stereoisomers
Jul 28, 2003: Neurocrine Biosciences Announces Initiation of Phase II Clinical Trial With NBI-5788 for Multiple Sclerosis
Jun 24, 2003: Neurocrine Biosciences Announces Positive Phase I Results With Its Proprietary, Orally Active GnRH Receptor Antagonist
Jun 23, 2011: Neurocrine Biosciences Announces Notice Of Allowance For Composition Of Matter Patent On VMAT2 Inhibitor
Dec 21, 2009: Neurocrine Announces VMAT2 Inhibitor
Feb 21, 2001: Neurocrine Biosciences Announces Expansion Of NBI-6024 Clinical Program To The United States
Dec 19, 2005: Neurocrine Biosciences Announces Positive Phase II Results Of Urocortin 2.
Sep 19, 2011: Neurocrine Biosciences Initiates Phase II Clinical Trial Of NBI-98854
Oct 18, 2010: Neurocrine Completes Reports Second Phase I Clinical Trial Of NBI-98854
Jul 17, 2001: Neurocrine Biosciences Announces Positive Phase II Results With NBI-34060 In Patients With Chronic Insomnia
Oct 14, 2002: Neurocrine Biosciences And Taisho Pharmaceutical Announces Agreement Restructuring
Jun 14, 2007: Neurocrine Biosciences Announces Resubmission Of NDA For Indiplon Capsules
Jun 14, 2002: Neurocrine Biosciences Reports Additional Phase I/II Safety Results With NBI-6024 In Adolescent Patients With Type 1 Diabetes
Dec 13, 2007: Neurocrine Receives Approvable Letter For Indiplon Capsules With Additional Safety And Efficacy Data Required By FDA
Apr 13, 2010: Neurocrine Biosciences Announces The Initiation Of Second VMAT2 Phase I Clinical Trial
Apr 13, 2010: Neurocrine Biosciences Begins Second VMAT2 Phase I Clinical Trial
May 10, 2001: Neurocrine Biosciences Updates Status Of NBI-34060 For The Treatment Of Insomnia
Jan 06, 2000: Neurocrine Biosciences, Inc. Signs Exclusive Agreement With Taisho Pharmaceuticals For European And Asian Rights To APL Diabetes
Apr 05, 2011: Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial For VMAT2 Inhibitor
Apr 04, 2000: Neurocrine Biosciences Inc. Announces Results On The Phase II Multiple Sclerosis Clinical Trial
Jan 03, 2002: Neurocrine Biosciences And Taisho Pharmaceutical Initiate A Pivotal Phase IIb Clinical Trial For NBI-6024
Dec 02, 1997: Neurocrine Biosciences Initiates Phase I Trial of Novel Therapeutic For Anxiety And Depression
May 01, 2003: Taisho Returns Japan Rights Of NBI-6024 To Neurocrine
Feb 01, 1999: Neurocrine Announces Phase Ib Clinical Trial Underway For Insomnia Compound
Financial Deals Landscape
Neurocrine Biosciences, Inc., Deals Summary
Neurocrine Biosciences, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Neurocrine Acquires Indiplon Royalty Stream From Wyeth
Partnerships
Neurocrine Biosciences Enters Into Collaboration Agreement With Boehringer Ingelheim
Abbott Laboratories Enters Into Co-Development Agreement With Neurocrine Biosciences
Pharmacopeia Drug Discovery Expands Its Agreement With Neurocrine Biosciences
Pharmacopeia Expanded Co-Development Agreement With Neurocrine
Licensing Agreements
Neurocrine Biosciences Enters Into Licensing Agreement With Dainippon Sumitomo Pharma
Neurocrine Biosciences Enters Into Licensing Agreement With Yissum Research Development Company
Genedata Enters Into Licensing Agreement With Neurocrine Biosciences
Neurocrine Biosciences Enters into Licensing Agreement With Almirall Prodesfarma
Equity Offering
Neurocrine Biosciences Completes Underwritten Public Offering Of $23 Million
Neurocrine Completes Private Placement Of $10 Million
Neurocrine Announces Private Placement Of $75 Million
Asset Transactions
Protox Therapeutics Acquires Assets From Neurocrine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Neurocrine Biosciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Neurocrine Biosciences, Inc. – Pipeline by Stage of Development, H2 2011
Neurocrine Biosciences, Inc. - Phase II, H2 2011
Neurocrine Biosciences, Inc. - Pipeline By Therapeutic Class, H2 2011
Neurocrine Biosciences, Inc. - Pipeline By Target, H2 2011
Neurocrine Biosciences, Inc. – Pipeline By Route of Administration, H2 2011
Neurocrine Biosciences, Inc. – Pipeline By Molecule Type, H2 2011
Neurocrine Biosciences, Inc. – Recent Pipeline Updates, H2 2011
Neurocrine Biosciences, Inc. - Dormant Developmental Projects, 2010
Neurocrine Biosciences, Inc. - Discontinued Pipeline Products, 2010
Neurocrine Biosciences, Inc., Subsidiaries
Neurocrine Biosciences, Inc., Deals Summary
Neurocrine Acquires Indiplon Royalty Stream From Wyeth
Neurocrine Biosciences Enters Into Collaboration Agreement With Boehringer Ingelheim
Abbott Laboratories Enters Into Co-Development Agreement With Neurocrine Biosciences
Pharmacopeia Drug Discovery Expands Its Agreement With Neurocrine Biosciences
Pharmacopeia Expanded Co-Development Agreement With Neurocrine
Neurocrine Biosciences Enters Into Licensing Agreement With Dainippon Sumitomo Pharma
Neurocrine Biosciences Enters Into Licensing Agreement With Yissum Research Development Company
Genedata Enters Into Licensing Agreement With Neurocrine Biosciences
Neurocrine Biosciences Enters into Licensing Agreement With Almirall Prodesfarma
Neurocrine Biosciences Completes Underwritten Public Offering Of $23 Million
Neurocrine Completes Private Placement Of $10 Million
Neurocrine Announces Private Placement Of $75 Million
Protox Therapeutics Acquires Assets From Neurocrine

LIST OF FIGURES

Neurocrine Biosciences, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Neurocrine Biosciences, Inc. – Pipeline by Stage of Development, H2 2011
Neurocrine Biosciences, Inc. – Pipeline By Therapeutic Class, H2 2011
Neurocrine Biosciences, Inc. - Pipeline By Target, H2 2011
Neurocrine Biosciences, Inc. – Pipeline By Molecule Type, H2 2011

Ask Your Question

Neurocrine Biosciences, Inc. – Product Pipeline Review – H2 2011
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: